150 related articles for article (PubMed ID: 29743937)
1. Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine.
López N; Torné A; Franco A; San-Martin M; Viayna E; Barrull C; Perulero N
Infect Agent Cancer; 2018; 13():15. PubMed ID: 29743937
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe.
Hartwig S; St Guily JL; Dominiak-Felden G; Alemany L; de Sanjosé S
Infect Agent Cancer; 2017; 12():19. PubMed ID: 28400857
[TBL] [Abstract][Full Text] [Related]
3. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
4. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of human papillomavirus-related diseases in Italy.
Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus-Attributable Cancers - United States, 2012-2016.
Senkomago V; Henley SJ; Thomas CC; Mix JM; Markowitz LE; Saraiya M
MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(33):724-728. PubMed ID: 31437140
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus.
Toh ZQ; Kosasih J; Russell FM; Garland SM; Mulholland EK; Licciardi PV
Infect Drug Resist; 2019; 12():1951-1967. PubMed ID: 31308715
[TBL] [Abstract][Full Text] [Related]
8. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
Pitisuttithum P; Velicer C; Luxembourg A
Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
[TBL] [Abstract][Full Text] [Related]
9. Human papilloma virus vaccines: Current scenario.
Pandhi D; Sonthalia S
Indian J Sex Transm Dis AIDS; 2011 Jul; 32(2):75-85. PubMed ID: 22021967
[TBL] [Abstract][Full Text] [Related]
10. Summary of the National Advisory Committee on Immunization's updated recommendations on human papillomavirus (HPV) vaccines: Nine-valent human papillomavirus (HPV) of minimum intervals between doses in the HPV immunization schedule.
Tunis MC; Deeks SL;
Can Commun Dis Rep; 2016 Jul; 42(7):149-151. PubMed ID: 29770021
[TBL] [Abstract][Full Text] [Related]
11. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark.
Olsen J; Jørgensen TR; Kofoed K; Larsen HK
BMC Public Health; 2012 Dec; 12():1082. PubMed ID: 23244352
[TBL] [Abstract][Full Text] [Related]
12. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
[TBL] [Abstract][Full Text] [Related]
13. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.
Signorelli C; Odone A; Ciorba V; Cella P; Audisio RA; Lombardi A; Mariani L; Mennini FS; Pecorelli S; Rezza G; Zuccotti GV; Peracino A
Epidemiol Infect; 2017 Jul; 145(10):1962-1982. PubMed ID: 28446260
[TBL] [Abstract][Full Text] [Related]
15. Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.
Simoens S; Bento-Abreu A; Merckx B; Joubert S; Vermeersch S; Pavelyev A; Varga S; Morais E
Front Pharmacol; 2021; 12():628434. PubMed ID: 33912045
[No Abstract] [Full Text] [Related]
16. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review.
Hartwig S; Syrjänen S; Dominiak-Felden G; Brotons M; Castellsagué X
BMC Cancer; 2012 Jan; 12():30. PubMed ID: 22260541
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom.
Owusu-Edusei K; Palmer C; Ovcinnikova O; Favato G; Daniels V
J Health Econ Outcomes Res; 2022; 9(1):140-150. PubMed ID: 35795155
[No Abstract] [Full Text] [Related]
18. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
19. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
20. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]